Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: IRWD

Ironwood Pharmaceuticals, Inc.

Healthcare | Drug Manufacturers - Specialty & Generic

No licensed closing price on file for IRWD. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$0.77

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) is a specialty and generic drug manufacturer. Figures from SEC EDGAR; updated 2026-10-21 09:57 UTC.

What Ironwood Pharmaceuticals, Inc. does

Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for gastrointestinal and rare diseases. The company's main commercial product is LINZESS (linaclotide), a GC-C agonist approved in the U.S. for treating irritable bowel syndrome with constipation and chronic idiopathic constipation in adults, and functional constipation in children ages 6-17, with availability in additional markets including Mexico, Japan, China, Canada, and certain European countries under various brand names.

Summarized from Ironwood Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$0.77
Return on equity-9.17%

Revenue, margins & earnings

FY2021 Revenue: $414M — margin split not shown (non-operating gains)FY2021: net income $528M exceeded revenue $414M by $115M — non-operating gains (e.g. asset sales), not operating profit$414MFY2021FY2022 Net income: $175MFY2022 Taxes & interest: $75MFY2022 Operating costs: $160M$411MFY2022FY2023: net loss $1.00B on revenue $443M$443MFY2023FY2024 Taxes & interest: $92MFY2024 Operating costs: $258M$351MFY2024FY2025 Net income: $24MFY2025 Taxes & interest: $74MFY2025 Operating costs: $198M$296MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net income above revenue (non-operating gains)
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
Gold cap: net income exceeded revenue that year from non-operating gains (e.g. asset sales), not operating profit.

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-17
  • 2026-09-17DirectorAward3,694—
  • 2026-07-22SVP, CMO, Head-Res&DrugAward137,036—
  • 2026-07-09PFO & PAOSale-127,890$578.1K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Ironwood Pharmaceuticals, Inc. do?

Ironwood Pharmaceuticals is a biotechnology company focused on developing and commercializing therapies for gastrointestinal and rare diseases.

When did IRWD last file with the SEC?

Ironwood Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-18. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 09:57 UTC. This page is also available as JSON at /api/data?ticker=IRWD and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for IRWD and 5,000+ tickers.

Create a free account — keep IRWD
For your agent
GET /api/data?ticker=IRWD

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt